P.539 Augmentative repetitive TMS in the treatment of poor responder depressed patients: a follow up study

2019 ◽  
Vol 29 ◽  
pp. S380-S381
Author(s):  
M.E.M. Vismara ◽  
C. Arici ◽  
L. Degoni ◽  
B. Grancini ◽  
V. De Carlo ◽  
...  
1983 ◽  
Vol 142 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Larry R. Squire ◽  
Pamela C. Slater

SummarySelf-reports of memory problems have been evaluated prospectively in depressed patients receiving bilateral ECT or unilateral ECT, and in depressed patients receiving treatments other than ECT. Depressed patients did not complain of poor memory at seven months after hospitalization. Compared to bilateral ECT, right unilateral ECT was associated with only mild memory complaints. At three years after treatment approximately one-half of the persons who had received bilateral ECT reported poor memory. These reports seemed to be influenced by three factors: (1) recurrence or persistence of conditions that were present before ECT; (2) the experience of amnesia initially associated with ECT and a subsequent tendency to question if memory had ever recovered; and (3) impaired memory for events that had occurred up to six months before treatment and up to about two months afterwards.


2000 ◽  
Vol 60 (2) ◽  
pp. 101-111 ◽  
Author(s):  
Henry Brodaty ◽  
Ian Hickie ◽  
Catherine Mason ◽  
Leanne Prenter

1988 ◽  
Vol 78 (1) ◽  
pp. 57-65 ◽  
Author(s):  
H. E. Lehmann ◽  
F. R. Fenton ◽  
M. Deutsch ◽  
S. Feldman ◽  
F. Engelsmann

Author(s):  
Ansen C Tse ◽  
Marcella LY Fok ◽  
Larina CL Yim ◽  
Meranda MW Leung ◽  
Chi-Ming Leung

2012 ◽  
Vol 27 (7) ◽  
pp. 513-517 ◽  
Author(s):  
B. Dell’Osso ◽  
S. Zanoni ◽  
R. Ferrucci ◽  
M. Vergari ◽  
F. Castellano ◽  
...  

AbstractTranscranial direct current stimulation (tDCS) is a selective, painless, brain stimulation technique that allows the electric stimulation of specific cortical regions. TDCS has been recently used as investigational intervention for major depression and treatment resistant depression (TRD) with encouraging results. The present study was aimed to investigate the efficacy and tolerability of tDCS in major depressives with poor response to pharmacological treatment. Twenty-three depressed patients, with a diagnosis of major depressive disorder or bipolar disorder, were treated with augmentative tDCS for 5 days, two sessions per day in a blind-rater trial. The course of depressive symptoms was analyzed using repeated measures ANOVA for HAM-D and MADRS total scores. A qualitative analysis on the basis of the HAM-D response was performed as well. Both analyses were conducted at three time-points: T0 (baseline), T1 (endpoint tDCS) and T2 (end of the first week of follow-up). All patients completed the trial without relevant side-effects. A significant reduction of HAM-D and MADRS total scores was observed during the study (P<0.0001). Treatment response (endpoint HAM-D reduction ≥50%) was obtained by four patients (17.4%) at T1 and by seven patients (30.4%) at T2 and remission (endpoint HAM-D<8) by three patients (13.0%) at T1 and by four subjects (17.4%) at T2. Present findings support the efficacy and good tolerability of tDCS in the acute treatment of patients with TRD with clinical benefit being progressive and extended to the first week of follow-up. Further sham-controlled trials with longer follow-up are needed to confirm present results.


Sign in / Sign up

Export Citation Format

Share Document